FDAnews Books Library

 

Gain Access to All Books and Reports

Our Books Library gives you year-round unrestricted access to all our books and reports.

They can be accessed, searched, downloaded and read anywhere, anytime. Topics covered include inspections, auditing, validation, recalls, pharmacovigilance, biosimilars, adverse events, QSR Data, supply chain, financial disclosure requirements and much more. You’ll automatically receive every new book we publish — we'll send you notifications to alert you of each new book in the library.  

And as an added bonus you’ll receive the most up-to-date editions of the FDA’s Code of Federal Regulations and its Investigations Operations Manual.

LOGIN

BUY NOW 1-Year Unlimited Access $997

 

Search by keyword (title of book maybe) or simply scroll through the list of titles to find what you need.

If you have any questions or are having any problems please give us a call on 703.538.7600 or email customer service.

Supplier Assessment Checklists: A Tool for Vetting Vendors and Contractors

Supplier Assessment Checklists: A Tool for Vetting Vendors and Contractors

December 9, 2019
What questions do you need to ask to make sure you select the best suppliers and contractors? This report includes two checklists — the API and Excipient Supplier Checklist and the Contract Manufacturing and Analysis Checklist — that will guide you through the process so that you dont have to worry about missing any points or asking the wrong questions.
Supplier Auditing: A Four-Part Plan

Supplier Auditing: A Four-Part Plan

December 9, 2019
You need a supplier auditing program that helps you stay on top of all your outsourced operations. The FDAnews Brief Supplier Auditing: A Four-Part Plan helps you build a system that shows the FDA and other regulators that you hold the reins when it comes to supplier quality.
Supplier Quality Metrics for Devicemakers: Predicting and Selecting the Best

Supplier Quality Metrics for Devicemakers: Predicting and Selecting the Best

December 9, 2019
Medical devicemaking relies on a supply chain that often includes hundreds of companies and stretches around the globe, a network so vast that quality control can seem impossible.In this management report youll learn how to use predictive analysis of such metrics as delivery time, management efficiency and lot acceptance rate to identify suppliers you can count on and spot potential problems in the future.
Surviving an FDA Inspection: 2015 Edition

Surviving an FDA Inspection: 2015 Edition

December 9, 2019
Under the FDA's new inspectorate reorganization, the agency is using specialized teams of highly trained investigators. This is making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips.
Social Media Accountability for Drug and Devicemakers: Controlling the Online Conversation

Social Media Accountability for Drug and Devicemakers: Controlling the Online Conversation

December 9, 2019
The FDA may not hold you responsible for reader comments, but they will watch for the way you respond. This management report gives you an understanding of how to use social media for product promotion without running afoul of the agency.
Social Media Strategies for Drug and Device Companies

Social Media Strategies for Drug and Device Companies

December 9, 2019
No matter how fast the rules continue to change, this new management report will help drug- and devicemakers tap the power of social media. you'll find real-world strategies for building a strong presence on Facebook, Twitter and YouTube - without giving up control over your brand or risking marketing and advertising enforcement. With little specific guidance from the FDA, this report fills a critical gap.
Special Protocol Assessment: Winning FDA Support for Trial Design

Special Protocol Assessment: Winning FDA Support for Trial Design

December 9, 2019
A new FDA draft guidance gives drug sponsors detailed advice on how to take advantage of the opportunity to have agency staff review your protocol before you begin your trial. This management report explains what kinds of trials are eligible, how the process works and what to do if the FDA doesnt agree with your plans.
Strategies for Biosimilars Approval: A Map to 351(k) Success

Strategies for Biosimilars Approval: A Map to 351(k) Success

December 9, 2019
Want to know how Sandoz was the FDA's first biosimilar approval? Learn how Sandoz navigated the agency's approval process. FDAnews has a new management report that will give you candid "what to do - and how to do it" advice. Discover how to minimize the amount of time it takes to get your biosimilars approved - so you can speed your product to market and maximize your revenue generating potential.
Risk-Based Monitoring of Clinical Trials 2017: New Trends and Best Practices

Risk-Based Monitoring of Clinical Trials 2017: New Trends and Best Practices

December 9, 2019
This report will show you, step-by-step, how to properly design and implement your risk-based clinical trial monitoring program to fully satisfy the FDAs requirements. You'll get specific recommendations about the 5 data points that you must always monitor … 9 essential critical risk factors your monitoring plan must consider … 5 key components that should make up your monitoring plan (and what they each should contain) … and all of the documentation requirements that are absolutely essential to every monitoring plan.
Root Cause Analysis for Drugs and Devices

Root Cause Analysis for Drugs and Devices

December 9, 2019
This management report provides a step-by-step guide to conducting an effective root cause analysis, from recognizing problems that need to be investigated to documenting the investigation so regulators can see you are on top of the situation. The report also includes root cause analysis templates readers can customize for their own investigation.
Smart Labeling Self-Audits: Prescriptions for Global Regulatory Compliance

Smart Labeling Self-Audits: Prescriptions for Global Regulatory Compliance

December 9, 2019
There's no doubt: complying with the detailed labeling requirements of every country in which you sell your products is a daunting task. But ... there is one established way to minimize your company's labeling errors and successfully sail through inspections. Setting up your own labeling self-audit programs. And this management report from FDAnews shows you how to do just that.
Regenerative Medicine: Steps to Accelerate Development

Regenerative Medicine: Steps to Accelerate Development

December 9, 2019
The Regenerative Medicine Advanced Therapy (RMAT) designation offers applicants an abbreviated pathway to approval, working closely with the FDA throughout the process. This report outlines the RMAT pathway and breaks down requirements regenerative medicine developers must meet to qualify.

Upcoming Events

Featured Products

Featured Stories

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More